New insulin candidate tested in 1,040 chinese diabetes patients
NCT ID NCT05834868
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tested a new insulin called THDB0206 against a standard insulin (lispro) in 1,040 Chinese adults with type 2 diabetes. Both groups also used a long-acting insulin (glargine). The goal was to see if the new insulin works as well or better at controlling blood sugar over 26 weeks. Participants had diabetes for at least 6 months and were already on insulin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.